Direct Costs Associated With Relapsed Diffuse Large B‐Cell Lymphoma Therapies

Oncologist - United States
doi 10.1634/theoncologist.2018-0490
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Alphamed Press